Skip to main content
SpringerLink
Log in

Interleukin-2

  • Conference paper
HIV-Infekt

  • 172 Accesses

Zusammenfassung

Durch die Entwicklung von Kombinationstherapien mit potenten antiretroviralen Medikamenten konnte die Therapie der HIV-Infektion deutlich verbessert und die Morbidität und Mortalität von AIDS-Patienten stark gesenkt werden. Bei Patienten mit fortgeschrittener Immundefizienz und starker CD4-Erniedrigung kann jedoch trotz einer guten Unterdrückung der HIV-Plasmavirämie oft kein oder nur ein unzureichender Anstieg der CD4-Zellzahlen erreicht werden. Als potentielle Ursachen für diese ungenügende immunologische Rekonstitution werden eine unzureichende Virushemmung in den lymphatischen Organen, eine massive Schädigung der lymphopoetischen Organen, eine Erschöpfung der lymphatischen Vorläuferzellen und ein Mangel an lymphopoetischen Zytokinen diskutiert. Für die fortgeschrittenen HIV-Patienten mit einer persistierenden CD4-Depletion werden daher zusätzliche Therapiestrategien benötigt, um das Immunsystem wieder so zu restaurieren, daß die Patienten auch langfristig vor opportunistischen Infektionen und Tumoren geschützt sind.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Blanco J, Cabrera C, Jou A, Ruiz L, Clotet B, Este JA (1999) Chemokine and chemokine receptor expression after combined anti-HIV-1 interleukin-2 therapy. Aids 13: 547–555

    Article  PubMed  CAS  Google Scholar 

  2. Carmichael A, Jin X, Sissons P, Borysiewicz L (1993) Quantitative analysis of the human immunodeficiency virus type I (HIV-1)-specifíc cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease. J Ex Med 177 (2): 249–256

    Article  CAS  Google Scholar 

  3. Chou SS, Ramili O, Vitetta ES (1997) Highly purified CD25-resting T cells cannot be infected de novo with HIV-1. Proc Natl Acad Sci USA 94: 1361–1365

    Article  PubMed  CAS  Google Scholar 

  4. Ciobanu N, Welte K, Kruger G, Salvatore V, Gold J, Feldman SP, Wang CY, Koziner B, Moore MAS, Bijan S, Mertelsmann R. (1993) Defective T-cell response to PHA and mitogenic monoclonal antibodies in male homosexuals with acquired immunodeficiency syndrome and its in vitro correction by interleukin-2. J Clin Immunol 3: 332–340

    Article  Google Scholar 

  5. Davey RT Jr, Chaitt DG, Albert JM, Piscitelli SC, Kovacs JA, Walker RE, Falloon J, Polis MA, Metcalf JA, Masur H, Dewar R, Baseler M, Fyfe G, Giedlin MA, Lane HC (1999) A randomized trial of high-versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection. J Infect Dis 179: 849–858

    Article  PubMed  CAS  Google Scholar 

  6. Ettinghausen SE, Moore JG, White DE, Platanias L, Young NS, Rosenberg SA (1987) Hematologic effects of immunotherapy with lymphokine-activated killercells and recombinant Interleukin-2 in cancer patients. Blood 69: 1654–1660

    PubMed  CAS  Google Scholar 

  7. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K, Lisziewicz J, Lori F, Flexner C, Quinn TC, Chaisson RE, Rosenberg E, Walker B, Gange S, Gallant J, Siliciano RF (1999) Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 5: 512–517

    Article  PubMed  CAS  Google Scholar 

  8. Gramatzki M, Burmester GR, Heyder N, Nüßlein HG, Rödl W, Grote W, Monner DA, Mühlradt PF, Kalden JR (1987) Intralymphatic interleukin-2 treatment of a hemophiliac AIDS patient with defective interleukin-2 production. Klin Wochenschr 65: 380–386

    Article  PubMed  CAS  Google Scholar 

  9. Gramatzki M, Nüsslein H, Burmester GR, Rodi W, Heyder N, Grote W, Monner DA, Mühlradt PF, Kalden JR (1986) Intralymphatic interleukin-2 treatment in patients with acquired immunodeficiency syndrome: preliminary experience in three cases. Immunobiology 172: 438–447

    PubMed  CAS  Google Scholar 

  10. Harrer E, Harrer T, Barbosa P, Feinberg M, Johnson RP, Buchbinder S, Walker BD (1996) Recognition of the highly conserved YMDD region in the human immunodeficiency virus type 1 reverse transcriptase by HLA-A2-restricted cytotoxic T lymphocytes from an asymptomatic long-term nonprogressor. J Infect Dis 173: 476–479

    Article  PubMed  CAS  Google Scholar 

  11. Harrer T, Harrer E, Kalams SA, Barbosa P, Trocha A, Johnson RP, Elbeik T, Feinberg M, Buchbinder S, Walker BD (1996) Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load. J Immunol 156: 2616–2623

    CAS  Google Scholar 

  12. Harrer T, Harrer E, Kalams SA, Elbeik T, Staprans SI, Feinberg MB, Cao Y, Ho DD, Yilma T, Caliendo AM, Johnson RP, Buchbinder SP, Walker BD (1996) Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. AIDS Res Hum Retroviruses 12: 585–592

    Article  PubMed  CAS  Google Scholar 

  13. Harrer T, Schwab J, Struff WG, Schmitt M, Ficker J, Rödl W, Parsch D, Kalden JR, Gramatzki M (1998) Therapy with AZT and intralymphatic natural IL-2 in patients with AIDS. Infection 26 (6): 368–374

    Article  PubMed  CAS  Google Scholar 

  14. Hengge UR, Goos M, Esser S, Exner V, Dotterer H, Wiehler H, Borchard C, Muller K, Beckmann A, Eppner MT, Berger A, Fiedler M (1998) Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy ( HAART) in HIV patients. Aids 12: 225–234

    Article  Google Scholar 

  15. Jacobson EL, Pilaro F, Smith KA (1996) Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity. Proc Natl Acad Sci USA: 10405–10110

    Google Scholar 

  16. Kern P, Toy J, Dietrich M (1985) Preliminary clinical observations with recombinant interleukin-2 in patients with AIDS or LAS. Blut 50: 1–6

    Article  PubMed  CAS  Google Scholar 

  17. Kinter AL, Bende SM, Hardy EC, Jackson R, Fauci AS (1995) Interleukin-2 induces CD8+ T cell mediated suppression of human immunodeficiency virus replication in CD4+ T-cells and this effect overrides its ability to stimulate virus expression. Proc Natl Acad Sci USA 92 (24): 10985–10989

    Article  PubMed  CAS  Google Scholar 

  18. Kovacs JA, Baseler M, Dewar RJ, Vogel S, Dayvey RT, Falloon J, Polis MA, Walker RE, Stevens R, Salzman NP, Metcalf JA, Masur H, Lane C (1995) Increases in CD4 T lymphocytes with intermittent courses of Interleukin-2 in patients with human immunodeficiency virus infection. N Engl J Med 332: 567–575

    Article  PubMed  CAS  Google Scholar 

  19. Kovacs JA, Vogel S, Jeffrey MA, Folloon J, Davey RT, Walker RE, Polis MA, Spooner K, Metcalf JA, Baseler M, Fyfe G, Lane HC (1996) Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med 335: 1350–1356

    Article  PubMed  CAS  Google Scholar 

  20. Lifson JD, Benike C, Mark DF, Koths K, Engleman EG (1984) Human rekombinant interleukin-2 partly reconstitutes deficient in-vitro immune responses of lymphocytes from patients with AIDS. Lancet i: 698–702

    Google Scholar 

  21. Lotze MT, Matory YL, Ettinghausen SE, Rayner AA, Sharrow SO, Seipp CAY, Custer MC, Rosenberg SA (1985) In vivo administration of purified human interleukin 2. II. Half live, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol 135: 2865–2875

    PubMed  CAS  Google Scholar 

  22. Meuer SC, Hussey RE, Penta AC, Fitzgerals KA, Stadler BM, Schlossman SF, Reinherz EL (1992) Cellular origin of interleukin-2 (IL 2) in man: evidence for stimulus restricted IL 2 production by T4+ and T+ lymphocytes. J Immunol 129: 1076–1081

    Google Scholar 

  23. Pitcher CJ, Quittner C, Peterson DM, Connors M, Koup RA, Maino VC, Picker LJ (1999) HIV-1-specifìc CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med 5: 518–525

    Article  PubMed  CAS  Google Scholar 

  24. Rook AH, Masur H, Lane HC, Frederick W, Kasahara T, Macher AM, Djeu JY, Manischewitz JF, Jackson L, Fauci A, Quinnan GV (1983) Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome. Journal of Clinical Investigation 72: 398–403

    Article  PubMed  CAS  Google Scholar 

  25. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, Walker BD (1997) Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 278: 1447–1450

    Article  PubMed  CAS  Google Scholar 

  26. Rosenberg ES, Walker BD (1998) HIV type i-specific helper T cells: a critical host defense. Aids Research & Human Retroviruses 14 Suppl 2: 143–147

    Google Scholar 

  27. Schwartz DH, Skowron G, Merigan TC (1991) Safety and effects of interleukin-2 plus zidovudine in asymptomatic individuals infected with human immunodeficiency virus. Journal of Acquired Immune Deficiency Syndromes 4: 11–23

    PubMed  CAS  Google Scholar 

  28. Simonelli C, Zanussi S, Cornar M, Vaccher E, Giacca M, De Paoli P, Tirelli U. (1998) Interleukin-2 in combination with zidovudine and didanosine is able to maintain high levels of CD4 cells and undetectable HIV viraemia [letter]. AIDS 1998 Jan 112:112–3XX

    Google Scholar 

  29. Swain SL (1991) Lymphokines and the immune resposne: the central role of interleukin-2. Curr Opin Immunol 3: 304

    Article  PubMed  CAS  Google Scholar 

  30. Taniguchi T, Minami Y (1993) The IL2/IL2 receptor system: a current overview. Cell 73: 5–8

    Article  PubMed  CAS  Google Scholar 

  31. Teppler H, Kaplan G, Smith KA, Montana AL, Meyn P, Cohn ZA (1993) Prolonged immunostimula- tory effect of low-dose polyethylene glycol interleukin 2 in patients with human immunodeficiency virus type 1 infection. J Exp Med 177: 483–492

    Article  PubMed  CAS  Google Scholar 

  32. Wagner R, Leschonsky B, Harrer E, Paulus C, Weber C, Walker BD, Buchbinder S, Wolf H, Kalden JR, Harrer T (1999) Molecular and functional analysis of a conserved CTL epitope in HIV-1p24 recognized from a long-term nonprogressor: constraints on immune escape associated with targeting a sequence essential for viral replication. J Immunol 162: 3727–3734

    PubMed  CAS  Google Scholar 

  33. Wood R, Montoya JG, Kundu SK, Schwartz DH, Merigan TC (1993) Safety and efficacy of polyethylene glycol-modified interleukin-2 and zidovudine in human immunodeficiency virus type 1 infection: a phase I/II study. J Infect Dis 167: 519–525

    Article  PubMed  CAS  Google Scholar 

  34. Zhang L, Ramratnam B, Tenner-Racz K, He Y, Vesanen M, Lewin S, Talal A, Racz P, Perelson AS, Korber BT, Markowitz M, Ho DD (1999) Quantifying residual HIV-i replication in patients receiving combination antiretroviral therapy. N Engl J Med 340: 1605–1613

    Article  PubMed  CAS  Google Scholar 

  35. Zou W, Foussat A, Houhou S, Durand-Gasselin I, Dulioust A, Bouchet L, Galanaud P, Levy Y, Emilie D (1999) Acute upregulation of CCR-5 expression by CD4+ T lymphocytes in HIV- infected patients treated with interleukin-2. ANRS 048 IL-2 Study Group. Aids 13: 455–463

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. T. Harrer
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik für Dermatologie, Allergologie und Venerologie, Ruhr-Universität Bochum, Gudrunstraße 56, Deutschland

    Norbert H. Brockmeyer , Klaus Hoffmann , G. Reimann , Markus Stücker  & Peter Altmeyer , , ,  & 

  2. Medizinische Klinik III, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt, Deutschland

    R. Brodt

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Harrer, T. (2000). Interleukin-2. In: Brockmeyer, N.H., Hoffmann, K., Reimann, G., Stücker, M., Altmeyer, P., Brodt, R. (eds) HIV-Infekt. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59683-4_45

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-59683-4_45

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-64082-7

  • Online ISBN: 978-3-642-59683-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation